FeesSafety
Pluang+

Johnson & Johnson's psoriasis drug Icotyde sales forecast raised to $4.5B peak by Bank of America

Analyst Insights
29 Sep 2026, 22:05 WIB
Proactive Investors
View Source
Bullish
Johnson & Johnson's psoriasis drug Icotyde sales forecast raised to $4.5B peak by Bank of America

Bank of America raised its peak sales forecast for Johnson & Johnson's oral psoriasis drug Icotyde to $4.5 billion, up from $2.4 billion, reflecting increased market share assumptions and a sector rerating favoring defensive stocks. The broker projects $70 million in sales for Q3 2026 and $220 million for the full year, aligning with consensus estimates. Despite limited prescription data, the firm maintained overall 2026 revenue forecasts at $25.5 billion with 6% growth, factoring in recent acquisitions and collaborations that increase R&D expenses. Investors should watch upcoming earnings for updates on Icotyde's launch and other product developments.

Johnson & Johnson shares are trading at USD 267.12 on Pluang as of September 30, 2026, 02:21 WIB, down 1.77% for the day. The stock's market cap stands at $655.37 billion, reflecting its significant presence in the health sector. Despite the recent downgrade in price, investors show a high sell activity of 94% on Pluang, indicating cautious sentiment around the stock amid its evolving product pipeline.

More News (JNJ)

Law firm investigates Johnson & Johnson over Q3 earnings miss and talc litigation charges

Law firm investigates Johnson & Johnson over Q3 earnings miss and talc litigation charges

Pomerantz LLP is investigating Johnson & Johnson for potential securities fraud following the company's Q3 2026 report, which showed a net earnings drop to $210 million due to large talc litigation charges and weak MedTech revenue growth. The investi...

Market News
Bearish
1 day ago
Investing $300K in Duke Energy, Philip Morris, and J&J yields $8,590 annually in steady dividends.

Investing $300K in Duke Energy, Philip Morris, and J&J yields $8,590 annually in steady dividends.

A $300,000 investment split equally among Duke Energy, Philip Morris, and Johnson & Johnson generates about $8,590 in annual passive income with a blended yield of 2.86%. Duke Energy offers the highest yield at 3.39%, followed closely by Philip Morri...

Bullish
2 days ago
CAPLYTA shows rapid, sustained improvement in bipolar mania symptoms, supporting FDA submission plans.

CAPLYTA shows rapid, sustained improvement in bipolar mania symptoms, supporting FDA submission plans.

Johnson & Johnson announced that CAPLYTA (lumateperone) met primary and key secondary endpoints in a Phase 3 study for treating manic episodes in bipolar I disorder, showing significant symptom improvement as early as Day 3 and sustained through Week...

Company Fundamentals
Bullish
2 days ago
4 dividend stocks—Duke Energy, P&G, J&J, JPMorgan—offer steady income despite divided U.S. government gridlock.

4 dividend stocks—Duke Energy, P&G, J&J, JPMorgan—offer steady income despite divided U.S. government gridlock.

Following the 2026 midterm elections resulting in a divided U.S. government, four dividend-paying blue-chip stocks—Duke Energy, Procter & Gamble, Johnson & Johnson, and JPMorgan Chase—are highlighted for their resilience amid legislative gridlock. Th...

Market News
Bullish
3 days ago
New dual-antigen immunotherapy shows strong PSA reductions in advanced prostate cancer Phase 1 trial

New dual-antigen immunotherapy shows strong PSA reductions in advanced prostate cancer Phase 1 trial

Johnson & Johnson announced promising Phase 1 results for a novel immunotherapy combining pasritamig and JNJ-9401, targeting two prostate cancer proteins to activate T cells. In the trial, 73% of patients saw PSA levels drop by at least 50%, with nea...

Company Fundamentals
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App